poisar

Stock

Syndax Pharmaceuticals, Inc. SNDX

$20.12+0.15%

Overview

SNDX market data

Price History

SNDX price chart · 1M
O
19.89
H
20.13
L
19.76
C
20.12
Vol
24,866.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$19.89
Previous Close
$20.09
Day High
$20.13
Day Low
$19.76
52 Week High
$25.20
52 Week Low
$16.67
7 Day Return
+1.87%
30 Day Return
+2.50%
90 Day Return
+2.71%
1 Year Return
-2.47%
Daily Notional Volume
$500.3K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.29
Diluted earnings per share over the trailing twelve months.
Beta
0.42
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-87.5%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$12.99 – $25.59
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1.7B · P/B 28.25 · P/S 6.91.

Company News

10 captured
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33Benzinga · Aug 21, 2026, 3:44 PM
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40Benzinga · Aug 11, 2026, 2:48 PM
Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.Benzinga · Aug 5, 2026, 1:00 PM
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38Benzinga · Aug 5, 2026, 11:10 AM
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M EstimateBenzinga · Aug 4, 2026, 8:03 PM
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price TargetBenzinga · Jul 15, 2026, 10:29 AM
8-K filing — Syndax Pharmaceuticals Inc (SNDX)SEC EDGAR · Jul 14, 2026, 12:30 PM
Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 CongressBenzinga · Jun 11, 2026, 11:11 AM
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical OncologyBenzinga · Jun 11, 2026, 11:09 AM
Syndax Pharma Enters Into Privately Negotiated Subscription Agreements For Issuance Of $250M Aggregate Principal Amount Of 2.25% Convertible Senior Notes Due 2031Benzinga · Jun 4, 2026, 11:20 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock